Clinical Trial

Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2020 (before its estimated April 10, 2023 completion). Its status may not reflect the trial's current state.
Summary
It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.
Trial Details
NCT Number NCT04316039
Lead Sponsor West China Hospital
Conditions Low-grade Glioma
Enrollment 250 participants
Start Date 2018-04-10
Primary Completion 2023-04-10 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2020-03-20